Publications
2 shownEvaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials
Our findings support that changes in plasma p-tau217 represent a robust endpoint for clinical trials targeting CU or CI individuals with Aβ pathology.
Frequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 2
- Citations
- 25
- Institution
- Brigham Young University
External Links
Identifiers
- ORCID
- 0000-0002-8501-545X
Impact Metrics
h-index
1
h-index: Number of publications with at least h citations each.